戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  participants were randomized: placebo, 356; lifitegrast, 355 (intention-to-treat [ITT] population).
2 eye (cyclosporine 0.05%, cyclosporine 0.09%, lifitegrast 5%, and loteprednol 0.25% eye drops and vare
3 omized 1:1 to receive topically administered lifitegrast (5.0%) or placebo (vehicle) twice daily for
4 mbined CSP and STD NMR experiments show that lifitegrast, a compound used for the treatment of dry ey
5 eving clinically meaningful improvement with lifitegrast across all sign and symptom end point pairs
6                                              Lifitegrast appeared well tolerated.
7 SS end point in demonstrating superiority of lifitegrast compared with placebo (P = 0.0007).
8  study evaluating the efficacy and safety of lifitegrast compared with placebo for the treatment of D
9 tation, discomfort) primarily on the initial lifitegrast dose at day 0.
10 eSure sealant to seal corneal incisions, and Lifitegrast for dry eye represent some of the major deve
11 nts (716 in the placebo group and 713 in the lifitegrast group) were analyzed.
12 that previously demonstrated the efficacy of lifitegrast in DED.
13                                              Lifitegrast is a lymphocyte function-associated antigen-
14                                              Lifitegrast is an integrin antagonist that decreases T-c
15           This is an interesting finding, as lifitegrast lends itself well as a blueprint for medicin
16                                              Lifitegrast met the co-primary symptom end point (eye dr
17  subjects were randomized: placebo, n = 360; lifitegrast, n = 358 (intent-to-treat population).
18 m baseline in EDS also significantly favored lifitegrast on days 42 (TE, 9.32; 95% CI, 5.44-13.20; P
19 mic emulsion 0.05% (Restasis((R)); CsA), and lifitegrast ophthalmic solution 5% (Xiidra((R)); LFT) ar
20 andomized 1:1 after 14-day placebo run-in to lifitegrast ophthalmic solution 5.0% or placebo twice da
21  run-in, participants were randomized 1:1 to lifitegrast ophthalmic solution 5.0% or placebo twice da
22                                              Lifitegrast ophthalmic solution 5.0% significantly reduc
23  An investigation of the treatment effect of lifitegrast ophthalmic solution, 5.0%, in different subg
24         These post hoc findings suggest that lifitegrast ophthalmic solution, 5.0%, treatment may be
25                                              Lifitegrast or placebo twice daily for 84 days.
26 Only unreliable systematic reviews evaluated lifitegrast, oral antibiotics, and moisture chamber devi
27 le systematic reviews are needed to evaluate lifitegrast, oral antibiotics, and moisture chamber devi
28                                              Lifitegrast significantly improved symptoms of eye dryne
29                                              Lifitegrast significantly reduced corneal fluorescein st
30                             Cyclosporine and lifitegrast, the 2 US Food and Drug Administration-appro
31        A greater improvement was observed in lifitegrast-treated participants at day 42 in itching (n
32                                   At day 84, lifitegrast-treated participants experienced significant
33                                         More lifitegrast-treated subjects (33.7%) than placebo-treate
34                                              Lifitegrast-treated subjects experienced greater improve
35 vement of secondary symptom end points among lifitegrast-treated subjects: ocular discomfort (nominal
36  study evaluating the efficacy and safety of lifitegrast versus placebo in participants with DED.
37 fort score (ODS), and safety/tolerability of lifitegrast versus placebo.
38 ponder and composite responder rates favored lifitegrast vs placebo (odds ratio range, 1.29 [95% CI,
39                                              Lifitegrast warrants further consideration as a treatmen